Oppenheimer analyst Steve Lichtman tells investors in a research note that he is a buyer of Tandem Diabetes (TNDM) shares on recent weakness and ahead of its September 25 Investor & Analyst Day. Lichtman says Tandem will bring the next advanced insulin pumps to market beyond Medtronic (MDT) with Basal-IQ rolling out now and Control-IQ in summer 2019, which position Tandem well to be a share gainer.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here